Literature DB >> 8923148

Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture.

D Ribatti1, A Vacca, M Iurlaro, R Ria, L Roncali, F Dammacco.   

Abstract

In vivo suppression of neovascularization by in situ administration of human recombinant interferon alpha 2a (hrIFN-alpha 2a) was tested on the chick embryo area vasculosa (AV). Methylcellulose discs, each containing 5 IU of hrIFN-alpha 2a were implanted onto the AV at Hamburger-Hamilton (HH) stage 13, and inhibition of blood vessel growth was morphometrically evaluated between HH stages 20 and 27. Our results show: (i) a decreased extent of the AV; (ii) a decreased AV total vessel length; (iii) modified percent ratios of different classes of AV vessels having a definite length. The observed effects of treating with hrIFN-alpha 2a are likely attributable to inhibition of endothelial cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923148     DOI: 10.1159/000179169

Source DB:  PubMed          Journal:  Int J Microcirc Clin Exp        ISSN: 0167-6865


  3 in total

1.  Tumor angiogenesis: insights and innovations.

Authors:  Fernando Nussenbaum; Ira M Herman
Journal:  J Oncol       Date:  2010-04-26       Impact factor: 4.375

2.  A 2-week pretreatment with 13-cis-retinoic acid + interferon-alpha-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers.

Authors:  J Dunst; G Hänsgen; U Krause; G Füchsel; U Köhler; A Becker
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

3.  Hypoxia generates a more invasive phenotype of tumour cells: an in vivo experimental setup based on the chorioallantoic membrane.

Authors:  Resit Demir; Lisa Naschberger; Ilknur Demir; Nathaniel Melling; Arno Dimmler; Thomas Papadopoulus; Michael Sturzl; Peter Klein; Werner Hohenberger
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.